Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAMBOCOR (flecainide) is an oral small-molecule antiarrhythmic agent approved in 1985 for the treatment of cardiac arrhythmias. The drug works by blocking cardiac sodium channels to restore normal heart rhythm. It is indicated for patients with documented ventricular arrhythmias and supraventricular tachycardia.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), career opportunities focus on defending market share through generic conversion strategies rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TAMBOCOR offers career experience in mature product management, generic transition strategy, and cost-containment initiatives under a lean organizational model. This role is best suited for professionals seeking expertise in lifecycle extension, pricing strategy, and defending market position in commoditized therapeutic areas.
Worked on TAMBOCOR at Alvogen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.